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Summary In rats a maximal tolerated dose of carboplatin (60mgkg-1, i.v.) caused severe anaemia,
leucopenia and thrombocytopenia. These indices of haematological toxicity were also observed with a
maximal tolerated dose of cis-platin (6.5mgkg-1, i.v.), but reductions in blood cell counts were less than
those observed with carboplatin. Anaemia was deduced to be the dose-limiting toxicity of carboplatin, since
red cell transfusions afforded protection to rats receiving a lethal dose of this compound (80mgkg-1, i.v.).
Anaemia did not appear to be due to an increase in the susceptibility of cis-platin- or carboplatin-exposed red
cells to lysis, as concluded from results of osmotic fragility tests. These red cells, when tagged with 51Cr, also
did not exhibit reductions in survival time. Administration of 5 Cr-labelled control red cells to rats, which
had been treated with carboplatin 3 days earlier, resulted in substantial loss of the radiolabel from the
circulation, indicating that internal haemorrhaging, as a result of thrombocytopenia, is probably the principle
cause ofdrug-induced anaemia.
The importance of cisplatin in cancer chemotherapy is
unequivocal. This square-planar platinum coordination
complex has demonstrated high antitumour activity against a
number of human cancers. In particular, it has played a
dominant role in the treatment of ovarian, testicular, bladder
and head and neck cancers (Prestayko et al., 1979). The
drug, however, has several drawbacks. The major limitation
of cisplatin is cumulative and irreversible nephrotoxicity
(Von Hoff & Rozencweig, 1979), although gastrointestinal
toxicity, peripheral neuropathy, ototoxicity and
haematological toxicity can also be severely restrictive
(Prestayko et al., 1979; Von Hoff & Rozencweig, 1979).
Carboplatin (JM8, CBDCA) is a new platinum complex
developed in our laboratory (Harrap et al., 1980), and
which, as Paraplatin, has recently been registered in the UK
for use against ovarian and lung cancers. The major
advantage of carboplatin is related to its favourable
spectrum of toxicity over the parent compound cis-platin.
Nephrotoxicity, ototoxicity or peripheral neuropathy, for
instance, is minimal or absent with carboplatin (Calvert et
al., 1982). The dose-limiting toxicity in patients receiving the
analogue has been reported as myelosuppression, mainly in
the form of thrombocytopenia (Calvert et al., 1982). As with
cis-platin, some patients have also developed anaemia during
treatment with carboplatin (Wiltshaw et al., 1983). It is likely
that myelosuppression is responsible for the carboplatin-
induced anaemia, which may manifest through a mechanism
involving either depression of erythropoietic activity, internal
haemorrhaging as a result of thrombocytopenia, or both.
Red cell lysis, however, cannot be ruled out as a
contributory factor in anaemia arising from carboplatin
administration since this toxic process is partly responsible
for giving rise to cis-platin-induced anaemia (Getaz et al.,
1980; Nguyen et al., 1981).
The purpose of this study was to compare temporally the
severities of anaemia, leucopenia and thrombocytopenia
caused by cis-platin and carboplatin, and to determine red
cell fragility and survival time in order to ascertain whether
the anaemia could be due to a direct lytic effect of the drug
on red cells.
Materials and methods
Chemicals
Cis-platin and carboplatin were generous gifts from the
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Johnson Matthey Research Centre (Sonning Common,
Reading, UK). The compounds were dissolved in 0.9%
saline or 5% dextrose, respectively, immediately before use.
Sodium [5'Cr] chromate (250-500 mCimg-1 chromium) as
an aqueous solution (1.0mCiml-1) was purchased from
Amersham (UK). Diacetyl monoxime was obtained from
Sigma and used in the determination of blood urea nitrogen
(BUN) as described by Crocker (1967). All reagents for
counting blood cells were purchased from Coulter
Electronics (UK).
Animals
Female Wistar rats (200-230g), bred at The Institute of
Cancer Research, were used throughout. Food and water
was allowed ad libitum. Both cis-platin and carboplatin were
administered i.v. (5mlkg-1) via a lateral tail vein. Control
rats received 0.9% saline (5mlkg-1, i.v.). Blood (0.20-
0.25ml) was collected from the tail following venepuncture,
transferred to microfuge tubes containing 5 units of heparin
and placed on ice.
Determination ofcell counts
Cell numbers were determined electronically as described by
Delaney and Garratty (1969). Red and white cells were
quantitated on a Coulter Counter (model ZF), using Isoton
as a diluent for blood and Zaponin as the red cell lysing
agent. The final blood dilutions for white and red cell counts
were 400- and 40,000-fold respectively. Platelets were
counted, at 8000-fold final dilution, on the Coulter
Thrombocounter-C using the platelet-rich supernatant
prepared from I ml of diluted (40-fold) blood on the Coulter
Thrombofuge.
Osmoticfragility ofred cells
Osmotic fragility was determined spectrophotometrically at
540nm as described by Dacie and Lewis (1975), using 25 I
blood samples diluted with 4.5ml of NaCI solution.
Survival ofred cells
A minor modification of the previously published method
(International Committee for Standardisation in
Haematology, 1971) was used to assess red cell survival.
Rats were anaesthetised with ether and - 5ml of blood was
removed from each animal via the abdominal aorta. The
blood was transferred to tubes containing 100 units of
heparin and then placed on ice. One ml samples were mixed
with 3ml PBS (0.9% saline buffered with 10mM-phosphate,
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pH 7.4) and centrifuged at 1200g for 5min. The supernatant
and buffy layer were removed and the residual red cells
washed with 3ml PBS/FCS (PBS containing 5% foetal calf
serum) by recentrifugation. The presence of FCS was
essential to minimise damage to cells by centrifugal forces.
The red cell pellet was resuspended in 2ml Dulbecco's
minimum essential medium containing 10% FCS, 100iCi of
51Cr was then added and the mixture incubated at 37°C for
30min in a shaking water-bath. After incubation, 3ml
PBS/FCS was added and the red cells pelleted by
centrifugation as before. The pellets were washed twice with
3ml PBS/FCS. Finally, the 51Cr-labelled cell pellets were
resuspended in 1 ml PBS and 0.6ml (2.5-3.0pCi) injected i.v.
(tail vein) into each recipient rat. Blood samples (0.20-
0.25ml) were collected from a tail vein into heparinised
microfuge tubes on day 1 and at regular intervals thereafter.
Aliquots (100pl) of blood were added to 1ml water and
51Cr counts determined in a gamma counter. Counts were
corrected for 5'Cr elution (Dacie & Lewis, 1975; Inter-
national Committee for Standardisation in Haematology,
1971) and then adjusted for decay by comparison with
counts of a standard solution prepared on day 0.
Haematocrits were determined in capillary tubes by
centrifuging at 1600g for 15min, and used to convert blood
volumes to packed cell volumes. The monoexponential
equation
C=Ae-" (where oc=rate constant)
was fitted to the data using a non-linear least squares
computer program (Jennrich & Sampson, 1968), with
1/(C+C)2 as the weighting factor (Ottaway, 1973).
Red cell transfusions
Untreated rats were used as blood donors. Blood was
collected from the abdominal aorta as before, cooled and
centrifuged in the cold at 1200g for 15min. The plasma and
buffy layer were removed, and the red cells washed twice in
2 volumes of cold 0.9% saline. The red cells were then
resuspended in saline to a final haematocrit of -0.5 (range
0.46-0.55), warmed and injected at 16mlkg-1 via the tail
vein into recipient rats. Controls received equivalent volumes
of warmed saline.
Results
At maximally tolerated doses of carboplatin (60mgkg-1,
i.v.) and cis-platin (6.5mgkg-1, i.v.) in rats, loss in body
weight was 6 and 11% respectively (Figure 1). These nadir
values occurred on day 4 for cis-platin and days 9-14 for
carboplatin. Body weights recovered to normal by days 16-
18. Nephrotoxicity was apparent at this dose of cis-platin, as
indicated by high BUN levels on day 4 (control,
21mg 0ml-m1; cis-platin, 112mg 100ml-'). BUN levels
were unchanged at all times following carboplatin
administration.
Maximally tolerated doses of the two platinum complexes
caused severe haematological toxicity, as indicated in Figure
2. Carboplatin produced over two-fold greater red cell
depression than cis-platin (62% vs. 24%), with nadirs
occurring on days 9-14 for both compounds. Recovery was
initiated soon after this time and was complete by day 18 for
cis-platin, but required more than 28 days in the case of
carboplatin. In contrast with anaemia, temporal profiles of
leucopenia differed for the two platinum complexes. With
cis-platin, the maximum decrease in white cells was 40% and
occurred on day 2. This was followed by a rapid recovery,
and cell counts were in fact 32% above normal by day 4,
returning to normal levels by day 9. With carboplatin, on
the other hand, leucopenia developed as fast over 2 days, but
instead of recovering, it progressed at a slower rate before
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Figure 1 Depression in body weights of rats receiving
carboplatin (D) (60mgkg-1, i.v.) or cis-platin (A) (6.5mgkg-1,
i.v.). Each group consisted of 6 rats initially, but one died in the
carboplatin group on day 10 and two died in the cis-platin group
on day 5. Results are presented as mean +s.e.
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Figure 2 The effect of carboplatin (-) (60mgkg-1, i.v.) and
cis-platin (A) (6.5mgkg-1, i.v.) on white and red cell and
platelet counts. Control values for red and white cell counts are
given in Table I. Platelet counts for the controls were
530+20 x 106ml- of blood. Results are presented as
mean +s.e.; n =4-6.
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Table I Relationship between anaemia or leucopenia and dose
Carboplatin Cisplatin
Dose RBCx 109 WBCx 106 Dose RBCx 109 WBCx 106
(mgkg 1) (day 9) (day 9) (mgkg-1) (day 9) (day 2)
0 6.5+0.2 13.2+0.7 0 6.9+0.2 11.2+1.4
10 6.3+0.1 12.6+0.5 1.25 7.1+0.4 11.0+1.5
20 6.3+0.2 10.1+0.3 2.5 6.7+0.2 9.0+0.3
40 5.4+0.2 8.0+0.5 5.0 6.3+0.3 9.3+1.5
50 5.0+0.4 5.7+0.6 6.5 5.5+0.2 6.7+0.7
60 2.5+0.6 3.5+0.4 8.0 6.7+0.2
80 1.2(n=1) 5.0 (n=1) 10.0 6.4+0.3
Rats received carboplatin or cis-platin i.v.
Data represent the red (RBC) and white (WBC) cell countsml- blood on the day
of nadir indicated in parentheses, and are shown as mean+s.e.; n=4-6 unless
otherwise stated.
making a later recovery. The maximum reduction in white
cell counts (74% on day 9) was almost 2-fold more severe
than with cis-platin. The overshoot in cell numbers was also
observed with carboplatin, but, in comparison with cis-
platin, the peak level (211% of control value) was greater
and occurred later (day 21). Recovery to normal levels
required more than 28 days to achieve following carbo-
platin administration. Like anaemia and leucopenia,
thrombocytopenia was also more severe with carboplatin
(86% redution) than with cis-platin (63%). Temporal aspects
of thrombocytopenia, however, were similar for both
compounds, with nadirs occurring on days 7-11, and
recovery by 4 weeks being preceded by increases in cell
numbers to almost twice normal values on days 17-22. Table
I indicates that the haematological toxicity was dose-
dependent, except at lethal doses when this dependency may
have been compromised by such factors as haemoconcen-
tration caused by renal failure or reduction in food and
water intake.
The day of nadir for anaemia coincides with the time of
death of rats receiving carboplatin, indicating that the severe
reduction in red cells is the probable cause of lethalities. In
order to test this, rats were given a lethal dose of carboplatin
(80mgkg-1, i.v.) followed by administration of red cells
from untreated animals a week later. A single red cell
transfusion on day 7 increased survival by 1-2 days (Table
Table II Protective effect of red cell transfusions on carboplatin-
induced lethalities
60-Day
Transfusion schedule n survivors Day ofdeath
Saline, day 7 7 0 9-10
Saline, days 7, 8, 9, 11 4 0 8-10
RBC, day 7 8 0 10-12
RBC, days 7, 8, 9, 11 8 7 14
Rats were given a lethal dose of carboplatin (80mgkg-1, i.v.),
and later received red cell transfusions either on day 7 alone or on
days 7, 8, 9 and 11. Controls received saline.
II). Multiple transfusions on days 7, 8, 9 and 11, however,
afforded protection to almost all animals, with only one rat
dying following extension in survival by about 5 days.
In an attempt to determine the underlying cause of
anaemia, osmotic fragility and survival times of red cells
from rats given maximal tolerated doses of cis-platin or
carboplatin 3 days earlier were determined. Red cells from
drug-treated animals, however, appeared to be only slightly
more fragile, but this increase in fragility was significant at
0.45% NaCl (Figure 3). Conversely, the concentration of
NaCl causing 50% haemolysis was significantly lower for
cells from drug-treated rats (Table III). Survival times, in
untreated rats, of "1Cr-labelled red cells from drug-treated
animals, on the other hand, were not significantly different
from controls (Figure 4, Table III). Chromium-tagged
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Figure 3 Osmotic fragility of red cells removed from rats
administered carboplatin (0) (60mgkg-1, i.v.) or cis-platin (A)
(6.5mgkg-1, i.v.) 3 days earlier. Results are presented as
mean+s.e.; n=3. An asterisk indicates P<0.05 vs. control (0)
by Student's t test.
Table III Osmotic fragility and survival time of red cells
Red cell survival
%NaCI causing Rate constant Half-life, Mean life-
Treatment 50% haemolysis ca(days 1) t1/2 (days) span (days)
Control 0.472+0.003 0.047+0.002 14.9+0.7 21.5+1.0
Carboplatin 0.460+0.002* 0.049+0.003 14.4+0.9 20.7+ 1.3
Cisplatin 0.449+0.006* 0.049+0.004 14.4+ 1.3 20.7+ 1.9
Blood was removed from rats 3 days after administering a maximally tolerated dose of
cis-platin (6.5 mgkg-1, i.v.) or carboplatin (60mgkg-1, i.v.). Red cells were tested for osmotic
fragility in vitro or used for 5'Cr-survival time determination in vivo in untreated rats.
Results are presented as mean+s.e.; n=3.
*P<0.05 vs. control, by Student's t test.days after administration of tagged cells. Thereafter, labelled
cells were lost by a slightly greater amount in the cis-platin
group than in controls, whilst cell loss from rats given
carboplatin was excessive. This excessive red cell loss for the
first 10 days, however, did not result in a substantial change
in the specific activity of the label when expressed as
cpmml-I packed red cells (Figure SB), indicating that both
endogenous and exogenous red cells were lost during the
development of carboplatin-induced anaemia. After this
time, the specific activity decreased rapidly probably as a
result of cell dilution during the process of recovery. The
specific activity with respect to packed cells in cis-platin-
treated animals was similar to control values at all times.
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Figure 4 Survival in untreated rats of red cells removed from
animals treated with carboplatin (i) (60mgkg-1, i.v.) or cis-
platin (A) (6.5mgkg-1, i.v.) 3 days earlier. Red cells were
tagged with 51Cr and administered i.v. into recipients. Results
are expressed as cpmml-1 packed red cells, and presented as
mean+s.e.; n=3. (O)=control.
a
200 -
-0 100-
0
- 50-
0
0
.0 25-
5)
10
E
3
0 5 10 15
Time (days)
20 25
b
LUU
Cu
m 'a
4- 0
-
l0
5)
0.
0
100
50 -
25 -
10
5-
0 5 10 15 20 25
Time (days)
Figure 5 Survival of control red cells in rats administered
carboplatin (0) (60mgkg-1, i.v.) or cis-platin (A) (6.5mgkg-1,
i.v.) 3 days earlier. Red cells were tagged with 5'Cr and given i.v.
to recipients. Results are expressed as cpmml-1 whole blood (A)
or cpmml-1 packed red cells (B), and presented as mean+s.e.;
n=3. (-)=control.
control red cells were also administered to rats which had
received maximal tolerated doses of cis-platin or carboplatin
3 days earlier. Results in Figure SA show that the specific
activity of the label expressed as cpmml - whole blood is
similar in controls and drug-treated groups during the first 4
Discussion
The differential nephrotoxicity of cis-platin and carboplatin
reported by Harrap et al., (1980) and Levine et al., (1981)
has been confirmed in this study. However, the results also
indicate that both cis-platin and carboplatin produce
haematological toxicity in rats, and that this toxicity is more
severe with carboplatin than with the parent drug. This
greater severity is the most probable reason for the observed
delayed recovery in cell counts in the carboplatin group as
compared to the cis-platin group. The temporal aspects of
cis-platin-induced leucopenia is similar to that reported in a
separate study in mice (Nowrousian & Schmidt, 1982). Cis-
platin, however, appears to elicit erythropenic effects in rats
different from those reported in mice (Nowrousian &
Schmidt, 1982), both in terms of severity and time course.
Whether this is indicative of a true species difference in the
toxic response is equivocal since rats (i.v.) and mice (i.p.)
received cis-platin by different routes. Leucopenia, anaemia
and thrombocytopenia are indeed common toxic features of
cis-platin in patients (Prestayko et al., 1979), although
nephrotoxicity, as in animals, is usually dose-limiting
(Prestayko et al., 1979; Von Hoff & Rozencweig, 1979).
In contrast to cis-platin, thrombocytopenia is the dose-
limiting toxicity of carboplatin in patients. Leucopenia is
also marked, and anaemia in some patients has been
troublesome enough to require blood transfusions (Calvert et
al., 1982; Wiltshaw et al., 1983). All these three forms of
myelosuppression have been demonstrated in rats with the
new platinum analogue. This study has indicated that
anaemia is the probable immediate cause of death since red
cell transfusions can protect from carboplatin-induced
lethalities. Protection, however, was not complete in that one
of the eight animals died after receiving four transfusions. It
is likely that additional transfusions would have afforded
total protection. It should be pointed out that red cell
preparations can contain platelets and some white cells
(Dacie & Lewis, 1975), so their involvement in providing
protection cannot be entirely excluded.
The underlying cause of drug-induced anaemia does not
appear to be related to an increase in the susceptibility of
erythrocytes to cell lysis, as judged from osmotic fragility
tests on red cells removed from rats three days after drug
administration. This conclusion is further strengthened by a
lack of effect of the platinum complexes on red cell half-lives
(t12= 14 days), which, as it appears, are similar to those
0112=10-21 days) reviewed by Belcher and Harriss (1959)
for normal rats. Drug-induced increase in osmotic fragility
or reduction in survival time of red cells, however, could
arise in rats after day 3 and may involve production of
antibodies against red cells, as has been reported in patients
receiving cis-platin (Getaz et al., 1980; Nguyen et al., 1981).
Depression of erythropoietic activity as an alternate
mechanism for the severe anaemia can almost certainly be
ruled out, since, in this case, anaemia would develop slowly,
if at all, as a result of the long mean red cell life span (21
days).
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Thrombocytopenia is probably the most likely cause of
anaemia, which would arise as a result of internal
haemorrhaging, particularly in the case of carboplatin.
Evidence for internal haemorrhaging is obtained from
studies on survival of control red cells in carboplatin-treated
rats. Since the 51Cr countsml-l packed red cells in these
rats were similar to controls in the face of severe anaemia on
days 7 and 10 after red cell administration (days 10 and 13
respectively after drug administration), it can be deduced
that tagged cells as well as host's own red cells were being
lost. Preferential loss of endogenous red cells as a result of
carboplatin administration otherwise would have resulted in
a substantial increase in specific activity of 5"Cr-tagged
packed cells. Further evidence for internal haemorrhaging in
carboplatin-treated rats comes from observations of slight
blood discharge from the anus of a few animals. It is
possible that the long duration of leucopenia in these
animals may also have been due to blood loss.
In conclusion, the dose-limiting toxicity of carboplatin in
rats is anaemia, which appears to be a secondary effect of
thrombocytopenia.
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